SCHEMBL3949459

SCHEMBL3949459

CCOC(=O)CCC(=O)c1ccccc1C

nearest known ligand 0.54

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
CTNNB1 P35222 8/20 0.54
WNT3A P56704 8/20 0.54
TSHR P16473 1/20 0.52
SMN1; SMN2 Q16637 2/20 0.50
ABCB1 P08183 1/20 0.49
CYP4F2 P78329 2/20 0.49
CYP4A11 Q02928 2/20 0.49
ERCC5 P28715 1/20 0.49
FEN1 P39748 1/20 0.49
MEN1 O00255 2/20 0.46
ALDH1A1 P00352 2/20 0.46
KMT2A Q03164 2/20 0.46
NPC1 O15118 1/20 0.46
GAA P10253 1/20 0.46
RAB9A P51151 1/20 0.46
TDP1 Q9NUW8 1/20 0.45
HSD17B10 Q99714 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30089517 0.85 CTNNB1 (0.68) CTNNB1WNT3AERCC5FEN1MEN1
SCHEMBL15979740 0.85 CTNNB1 (0.68) CTNNB1WNT3AERCC5FEN1MEN1
SCHEMBL13962647 0.85 CYP4F2 (0.55) TSHRSMN1; SMN2ABCB1CYP4F2CYP4A11
SCHEMBL9348474 0.85 TSHR (0.50) CTNNB1TSHRSMN1; SMN2ABCB1CYP4F2
SCHEMBL9737218 0.85 SMN1; SMN2 (0.53) TSHRSMN1; SMN2ABCB1CYP4F2CYP4A11
SCHEMBL9374658 0.85 TSHR (0.70) TSHRSMN1; SMN2ABCB1CYP4F2CYP4A11
SCHEMBL406193 0.84 ERCC5 (0.59) TSHRSMN1; SMN2ERCC5FEN1MEN1
SCHEMBL15778916 0.83 TSHR (0.49) TSHRSMN1; SMN2ABCB1CYP4F2CYP4A11
SCHEMBL31520096 0.83 ALDH1A1 (0.63) TSHRSMN1; SMN2ABCB1CYP4F2CYP4A11
SCHEMBL6865172 0.83 ALDH1A1 (0.63) TSHRSMN1; SMN2ABCB1CYP4F2CYP4A11

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8865707-B2 Cholesteryl ester transfer protein inhibitors MERCK SHARP & DOHME CORP. (US) 2014-10-21 US disclosed
EP-1973546-B1 CHOLESTERYL ESTER TRANSFER PROTEIN INHIBITORS MERCK SHARP & DOHME (US) 2012-06-13 EP disclosed
US-20090280977-A1 PROCESS FOR PREPARING CATALYST COMPONENTS FOR THE POLYMERIZATION OF OLEFINS BASELL POLIOLEFINE ITALIA S.R.L (IT) 2009-11-12 US disclosed
EP-2051999-A1 PROCESS FOR PREPARING CATALYST COMPONENTS FOR THE POLYMERIZATION OF OLEFINS Basell Poliolefine Italia S.r.l. (IT) 2009-04-29 EP disclosed
US-20090018054-A1 Cholesteryl Ester Transfer Protein Inhibitors MERCK SHARP & DOHME LLC 2009-01-15 US disclosed
EP-1973546-A2 CHOLESTERYL ESTER TRANSFER PROTEIN INHIBITORS Merck & Co., Inc. (US) 2008-10-01 EP disclosed
WO-2008019802-A1 PROCESS FOR PREPARING CATALYST COMPONENTS FOR THE POLYMERIZATION OF OLEFINS BASELL POLIOLEFINE ITALIA S.R.L. (DE) 2008-02-21 WO disclosed
WO-2007081570-A2 CHOLESTERYL ESTER TRANSFER PROTEIN INHIBITORS MERCK & CO., INC. (US) 2007-07-19 WO disclosed
EP-0849291-B1 Catalyst for olefin polymerization and method for preparing polyolefins JAPAN POLYOLEFINS CO LTD (JP) 2002-02-13 EP disclosed
US-6271167-B1 TRIMETHOXYSILANE COMPOUND JAPAN POLYOLEFINS CO., LTD. (JP) 2001-08-07 US disclosed
EP-0849291-A1 Catalyst for olefin polymerization and method for preparing polyolefins Japan Polyolefins Co., Ltd. (JP) 1998-06-24 EP disclosed
US-5693729-A STEREOSPECIFIC CATALYZING IN PRESENCE OF A MIXTURE CONSISTING OF A TITANIUM AND A MAGNESIUM COMPOUND, AN ORGANOALUMINUM COMPOUND OR AN ALUMOXANE, AN ORGANOSILICON COMPOUND SHOWA DENKO K.K. (JP) 1997-12-02 US disclosed
EP-0578473-B1 Catalyst for polymerization of olefin and process for producing olefin polymer SHOWA DENKO KK (JP) 1997-11-19 EP disclosed
EP-0640624-B1 Catalyst for polymerization of olefin and process for the preparation of olefin polymer SHOWA DENKO KK (JP) 1997-06-18 EP disclosed
EP-0717053-A2 Catalyst for olefin polymerization and process for producing polyolefin using the same JAPAN POLYOLEFINS CO., LTD. (JP) 1996-06-19 EP disclosed
EP-0704424-A1 3-alkoxypropionic ester derivative, olefin polymerization catalyst, and process for preparation of polyolefin SHOWA DENKO KABUSHIKI KAISHA (JP) 1996-04-03 EP disclosed
US-5476825-A Consists of magnesium, titanium and halogen compounds, an organoaluminum compound, a reaction product of organoaluminum or organoboron compound with organosilicon compound SHOWA DENKO K.K. (JP) 1995-12-19 US disclosed
US-5407883-A Containing magnesium, titanium, aluminum and silicon compounds including polymeric aluminum and alumoxanes SHOWA DENKO K.K. (JP) 1995-04-18 US disclosed
EP-0640624-A1 Catalyst for polymerization of olefin and process for the preparation of olefin polymer SHOWA DENKO KABUSHIKI KAISHA (JP) 1995-03-01 EP disclosed
EP-0578473-A1 Catalyst for polymerization of olefin and process for producing olefin polymer SHOWA DENKO KABUSHIKI KAISHA (JP) 1994-01-12 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090018054-A1 Cholesteryl Ester Transfer Protein Inhibitors CETP, APOB, MTTP CTNNB1 1467/4885WNT3A 1779/4885TSHR 4007/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.